Exploring the Landscape of Anti-Inflammatory Trials: A Comprehensive Review of Strategies for Targeting Inflammation in Acute Myocardial Infraction

• Published in: Biomedicines Vol. 12; no. 3; p. 701
• Main Authors: Mitsis, Andreas, Kyriakou, Michaela, Sokratous, Stefanos, Karmioti, Georgia, Drakomathioulakis, Michail, Myrianthefs, Michael, Ziakas, Antonios, Tzikas, Stergios, Kassimis, George
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Acute coronary syndromes; acute myocardial infarction; Anti-inflammatory agents; Anti-inflammatory drugs; anti-inflammatory interventions; Atherosclerosis; canakinumab; Clinical outcomes; Clinical trials; colchicine; coronary artery disease; Cytokines; Heart attack; Heart attacks; IL-6; Inflammation; Kinases; Mortality; Myocardial infarction; Review; Stroke; Thrombosis; Tumor necrosis factor-TNF; Type 2 diabetes; coronary artery disease; canakinumab; inflammation; anti-inflammatory interventions; colchicine; IL-6; acute myocardial infarction
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12030701

The role of inflammation in the pathophysiology of acute myocardial infarction (AMI) is well established. In recognizing inflammation's pivotal role in AMI, this manuscript systematically traces the historical studies spanning from early attempts to the present landscape. Several anti-inflammatory trials targeting inflammation in post-AMI have been performed, and this review includes the key trials, as well as examines their designs, patient demographics, and primary outcomes. Efficacies and challenges are analyzed, thereby shedding light on the translational implications of trial outcomes. This article also discusses emerging trends, ongoing research, and potential future directions in the field. Practical applications and implications for clinical practice are considered by providing a holistic view of the evolving landscape of anti-inflammatory interventions in the context of AMI.